Table 3.
Most frequently reported treatment‐emergent adverse events with incidence > 1 event per 100 patient‐years
| Preferred term | Continuous risankizumab 150 mg |
|---|---|
| n = 897; PYs = 3106·2 | |
| Nasopharyngitis | 537 (17·3) |
| Upper respiratory tract infection | 332 (10·7) |
| Arthralgia | 119 (3·8) |
| Headache | 96 (3·1) |
| Hypertension | 87 (2·8) |
| Back pain | 86 (2·8) |
| Influenza | 78 (2·5) |
| Sinusitis | 68 (2·2) |
| Bronchitis | 62 (2·0) |
| Gastroenteritis | 60 (1·9) |
| Urinary tract infection | 51 (1·6) |
| Diarrhoea | 49 (1·6) |
| Cough | 44 (1·4) |
| Contact dermatitis | 42 (1·4) |
| Oropharyngeal pain | 37 (1·2) |
| Injection‐site erythema | 36 (1·2) |
| Fatigue | 35 (1·1) |
| Osteoarthritis | 33 (1·1) |
| Pruritus | 33 (1·1) |
| Tinea pedis | 33 (1·1) |
The data are presented as the number of events per 100 PYs. PY, patient‐years.